These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 34252181)

  • 1. PCSK9 deficiency rewires heart metabolism and drives heart failure with preserved ejection fraction.
    Da Dalt L; Castiglioni L; Baragetti A; Audano M; Svecla M; Bonacina F; Pedretti S; Uboldi P; Benzoni P; Giannetti F; Barbuti A; Pellegatta F; Indino S; Donetti E; Sironi L; Mitro N; Catapano AL; Norata GD
    Eur Heart J; 2021 Aug; 42(32):3078-3090. PubMed ID: 34252181
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PCSK9 deficiency reduces insulin secretion and promotes glucose intolerance: the role of the low-density lipoprotein receptor.
    Da Dalt L; Ruscica M; Bonacina F; Balzarotti G; Dhyani A; Di Cairano E; Baragetti A; Arnaboldi L; De Metrio S; Pellegatta F; Grigore L; Botta M; Macchi C; Uboldi P; Perego C; Catapano AL; Norata GD
    Eur Heart J; 2019 Jan; 40(4):357-368. PubMed ID: 29982592
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ascorbic acid enhances low-density lipoprotein receptor expression by suppressing proprotein convertase subtilisin/kexin 9 expression.
    Wang D; Yang X; Chen Y; Gong K; Yu M; Gao Y; Wu X; Hu H; Liao C; Han J; Duan Y
    J Biol Chem; 2020 Nov; 295(47):15870-15882. PubMed ID: 32913121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Asialoglycoprotein receptor 1 is a novel PCSK9-independent ligand of liver LDLR cleaved by furin.
    Susan-Resiga D; Girard E; Essalmani R; Roubtsova A; Marcinkiewicz J; Derbali RM; Evagelidis A; Byun JH; Lebeau PF; Austin RC; Seidah NG
    J Biol Chem; 2021 Oct; 297(4):101177. PubMed ID: 34508778
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration.
    Zaid A; Roubtsova A; Essalmani R; Marcinkiewicz J; Chamberland A; Hamelin J; Tremblay M; Jacques H; Jin W; Davignon J; Seidah NG; Prat A
    Hepatology; 2008 Aug; 48(2):646-54. PubMed ID: 18666258
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cyclase-associated protein 1 is a binding partner of proprotein convertase subtilisin/kexin type-9 and is required for the degradation of low-density lipoprotein receptors by proprotein convertase subtilisin/kexin type-9.
    Jang HD; Lee SE; Yang J; Lee HC; Shin D; Lee H; Lee J; Jin S; Kim S; Lee SJ; You J; Park HW; Nam KY; Lee SH; Park SW; Kim JS; Kim SY; Kwon YW; Kwak SH; Yang HM; Kim HS
    Eur Heart J; 2020 Jan; 41(2):239-252. PubMed ID: 31419281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Substantial PCSK9 inactivation in β-cells does not modify glucose homeostasis or insulin secretion in mice.
    Peyot ML; Roubtsova A; Lussier R; Chamberland A; Essalmani R; Murthy Madiraju SR; Seidah NG; Prentki M; Prat A
    Biochim Biophys Acta Mol Cell Biol Lipids; 2021 Aug; 1866(8):158968. PubMed ID: 33992809
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PCSK9 deficiency results in a specific shedding of excess LDLR in female mice only: Role of hepatic cholesterol.
    Roubtsova A; Garçon D; Lacoste S; Chamberland A; Marcinkiewicz J; Métivier R; Sotin T; Paquette M; Bernard S; Cariou B; Le May C; Koschinsky ML; Seidah NG; Prat A
    Biochim Biophys Acta Mol Cell Biol Lipids; 2022 Dec; 1867(12):159217. PubMed ID: 35985474
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2.
    Poirier S; Mayer G; Benjannet S; Bergeron E; Marcinkiewicz J; Nassoury N; Mayer H; Nimpf J; Prat A; Seidah NG
    J Biol Chem; 2008 Jan; 283(4):2363-72. PubMed ID: 18039658
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human PCSK9 promotes hepatic lipogenesis and atherosclerosis development via apoE- and LDLR-mediated mechanisms.
    Tavori H; Giunzioni I; Predazzi IM; Plubell D; Shivinsky A; Miles J; Devay RM; Liang H; Rashid S; Linton MF; Fazio S
    Cardiovasc Res; 2016 May; 110(2):268-78. PubMed ID: 26980204
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activation of Adiponectin Receptor Regulates Proprotein Convertase Subtilisin/Kexin Type 9 Expression and Inhibits Lesions in ApoE-Deficient Mice.
    Sun L; Yang X; Li Q; Zeng P; Liu Y; Liu L; Chen Y; Yu M; Ma C; Li X; Li Y; Zhang R; Zhu Y; Miao QR; Han J; Duan Y
    Arterioscler Thromb Vasc Biol; 2017 Jul; 37(7):1290-1300. PubMed ID: 28546220
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diet-induced hepatic steatosis abrogates cell-surface LDLR by inducing
    Lebeau PF; Byun JH; Platko K; MacDonald ME; Poon SV; Faiyaz M; Seidah NG; Austin RC
    J Biol Chem; 2019 Jun; 294(23):9037-9047. PubMed ID: 31004037
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum proprotein convertase subtilisin/kexin type 9 and cell surface low-density lipoprotein receptor: evidence for a reciprocal regulation.
    Tavori H; Fan D; Blakemore JL; Yancey PG; Ding L; Linton MF; Fazio S
    Circulation; 2013 Jun; 127(24):2403-13. PubMed ID: 23690465
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proprotein convertase subtilisin kexin type 9 promotes intestinal overproduction of triglyceride-rich apolipoprotein B lipoproteins through both low-density lipoprotein receptor-dependent and -independent mechanisms.
    Rashid S; Tavori H; Brown PE; Linton MF; He J; Giunzioni I; Fazio S
    Circulation; 2014 Jul; 130(5):431-41. PubMed ID: 25070550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatic overexpression of idol increases circulating protein convertase subtilisin/kexin type 9 in mice and hamsters via dual mechanisms: sterol regulatory element-binding protein 2 and low-density lipoprotein receptor-dependent pathways.
    Sasaki M; Terao Y; Ayaori M; Uto-Kondo H; Iizuka M; Yogo M; Hagisawa K; Takiguchi S; Yakushiji E; Nakaya K; Ogura M; Komatsu T; Ikewaki K
    Arterioscler Thromb Vasc Biol; 2014 Jun; 34(6):1171-8. PubMed ID: 24675665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proprotein convertase subtilisin/kexin 9 V4I variant with LDLR mutations modifies the phenotype of familial hypercholesterolemia.
    Ohta N; Hori M; Takahashi A; Ogura M; Makino H; Tamanaha T; Fujiyama H; Miyamoto Y; Harada-Shiba M
    J Clin Lipidol; 2016; 10(3):547-555.e5. PubMed ID: 27206942
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Single Domain Antibodies Are Potent Inhibitors of Low Density Lipoprotein Receptor Degradation.
    Weider E; Susan-Resiga D; Essalmani R; Hamelin J; Asselin MC; Nimesh S; Ashraf Y; Wycoff KL; Zhang J; Prat A; Seidah NG
    J Biol Chem; 2016 Aug; 291(32):16659-71. PubMed ID: 27284008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mice Fed a High-Cholesterol Diet Supplemented with Quercetin-3-Glucoside Show Attenuated Hyperlipidemia and Hyperinsulinemia Associated with Differential Regulation of PCSK9 and LDLR in their Liver and Pancreas.
    Mbikay M; Mayne J; Sirois F; Fedoryak O; Raymond A; Noad J; Chrétien M
    Mol Nutr Food Res; 2018 May; 62(9):e1700729. PubMed ID: 29396908
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PCSK9 deficiency unmasks a sex- and tissue-specific subcellular distribution of the LDL and VLDL receptors in mice.
    Roubtsova A; Chamberland A; Marcinkiewicz J; Essalmani R; Fazel A; Bergeron JJ; Seidah NG; Prat A
    J Lipid Res; 2015 Nov; 56(11):2133-42. PubMed ID: 26323289
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PCSK9 deficiency results in increased ectopic fat accumulation in experimental models and in humans.
    Baragetti A; Balzarotti G; Grigore L; Pellegatta F; Guerrini U; Pisano G; Fracanzani AL; Fargion S; Norata GD; Catapano AL
    Eur J Prev Cardiol; 2017 Nov; 24(17):1870-1877. PubMed ID: 28758421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.